PANews reported on September 9 that Nasdaq-listed Artelo Biosciences (NASDAQ: ARTL) announced the launch of an underwritten public offering of common stock and/or prepaid warrants, with RF Lafferty & Co., Inc. serving as the sole bookrunner.
Additionally, Artelo announced a $9.475 million private fundraising plan to launch its financial strategy based on the Solana blockchain, becoming one of the first companies to adopt the Solana cryptocurrency as its core reserve asset.
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.